Cargando…

Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection

INTRODUCTION: Randomized trials and observational studies have consistently reported rates of sustained virological response (SVR), equivalent to hepatitis C virus (HCV) cure, as high as 95% following treatment with direct‐acting antiviral (DAA) treatment in individuals with HIV and HCV co‐infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodi, Sara, Klein, Marina, Rauch, Andri, Epstein, Rachel, Wittkop, Linda, Logan, Roger, Rentsch, Christopher T., Justice, Amy C., Touloumi, Giota, Berenguer, Juan, Jarrin, Inma, Egger, Matthias, Puoti, Massimo, D'Arminio Monforte, Antonella, Gill, John, Salmon Ceron, Dominique, van Sighem, Ard, Linas, Benjamin, van der Valk, Marc, Hernán, Miguel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784654/ https://www.ncbi.nlm.nih.gov/pubmed/36562643 http://dx.doi.org/10.1002/jia2.26048

Ejemplares similares

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration
por: Touloumi, Giota, et al.
Publicado: (2013)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

Towards standardized definitions for monitoring the continuum of HIV care in Europe
por: Gourlay, Annabelle J., et al.
Publicado: (2017)

Illness Representations of HIV Positive Patients Are Associated with Virologic Success
por: Leone, Daniela, et al.
Publicado: (2016)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
por: Atkinson, Andrew, et al.
Publicado: (2020)

Relating protease inhibitor resistance at time of virological failure with drug exposure
por: Van Luin, M, et al.
Publicado: (2010)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis
por: Willemse, Sophie, et al.
Publicado: (2019)

Moving towards zero new HIV infections: The importance of combination prevention
por: van Sighem, Ard, et al.
Publicado: (2022)

Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region
por: Porter, Kholoud, et al.
Publicado: (2018)

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada
por: Ruiz-Burga, Elisa, et al.
Publicado: (2023)

Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings
por: Trickey, Adam, et al.
Publicado: (2019)

T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis
por: Merlini, Esther, et al.
Publicado: (2012)

sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies
por: Loosli, Tom, et al.
Publicado: (2023)

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders
por: Giancola, Maria Letizia, et al.
Publicado: (2012)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?
por: Vourli, Georgia, et al.
Publicado: (2020)

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature
por: Tincati, Camilla, et al.
Publicado: (2018)

Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection
por: Lodi, S, et al.
Publicado: (2010)

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies
por: Kaulich-Bartz, Josee, et al.
Publicado: (2013)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
por: Chereau, Fanny, et al.
Publicado: (2017)

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study
por: Marchetti, Giulia, et al.
Publicado: (2014)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Higher rates of triple‐class virological failure in perinatally HIV‐infected teenagers compared with heterosexually infected young adults in Europe
por: Judd, A, et al.
Publicado: (2016)

The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges
por: Gourlay, Annabelle, et al.
Publicado: (2017)

Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?
por: Tincati, Camilla, et al.
Publicado: (2020)

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?
por: Shanyinde, Milensu, et al.
Publicado: (2019)

Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Geretti, Anna Maria, et al.
Publicado: (2013)

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study
por: Caniglia, Ellen C., et al.
Publicado: (2016)

HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors
por: Paraskevis, Dimitrios, et al.
Publicado: (2019)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy
por: Nozza, Silvia, et al.
Publicado: (2021)

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
por: Merlini, E, et al.
Publicado: (2010)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection
por: Augello, Matteo, et al.
Publicado: (2023)

HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review
por: Vourli, Georgia, et al.
Publicado: (2021)

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients
por: Saracino, Annalisa, et al.
Publicado: (2018)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_msebuucqjvt02d87khdcrlna7q